Abstract 375P
Background
The NAME study aims at investigating whether the treatment with Navelbine, according to the metronomic principle, is superior to conventional treatment in terms of efficacy and safety. The study has the EUDRACT no: 2016-002165-63. In addition to better efficacy, preliminary studies show treatment with frequent small dosages, not only have an effect on the tumour cells, but also, an effect on the angiogenesis and the immune cells.
Methods
The NAME trial is an open randomized multicentre phase II study. We included 163 patients with HER2 normal metastatic breast cancer in Denmark from 2017-2022. Both patients with Estrogenic receptor (ER) positive and ER negative tumours were included in the study. The randomisation is between the standard Arm A, where the patients are treated with Vinorelbine (Navelbine Oralâ): 60 mg/m2 day 1 and day 8, every three weeks for the first cycle. Hereafter 80 mg/m2 in the following cycles. In the metronomic experimental Arm B, the patients receive Vinorelbine (Navelbine Oralâ): daily doses of Navelbine. The start dose is 30 mg per day. Reduction is possible.
Results
The patients were well balanced between the two arms. Median age were 68-69 years. Primarily performance status 0-1. The adverse events found in the study shows the two regimes were both well tolerated with mostly low-grade adverse events. We found a median progression free survival (PFS) in arm A of 3.9 months (95% CI 3.4-4.5) and a median PFS in arm B of 2.3 months (95% CI 1.5-3.0). The difference was non-significant (P=0.236). The median overall survival (OS) was 16.63 months (95% CI 14.66-18.61) in arm A and 15.13 months (95% CI 12.11-18.16) in arm B. Also, non-significant (P=0.355).
Conclusions
The study was conducted in order investigate metronomic chemotherapy using a randomized trial design. There was no significant difference between the two arms regarding effect. No new signals regarding safety were observed. While metronomic chemotherapy may offer certain advantages, our findings could not demonstrate any benefit, when using Navelbine in advanced breast cancer patients in this particular investigator initiated, multicentre, Danish randomised controlled trial, the NAME trial.
Clinical trial identification
EudraCT 2016-002165-63 The NAME trial.
Editorial acknowledgement
Legal entity responsible for the study
Anne Sofie Brems-Eskildsen.
Funding
Pierre Fabre, Overture's Torg 1, Plan 2 SE-19147 Sollentuna Sweden.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
435TiP - Molecular imaging of programmed death ligand 1 (PD-L1) expression with [89Zr]Zr-atezolizumab positron emission tomography/computed tomography (PET/CT) in patients with metastatic triple negative breast cancer (mTNBC): The MIMIR-study
Presenter: Renske Altena
Session: Poster session 15
Resources:
Abstract
436TiP - DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer
Presenter: Joyce O'Shaughnessy
Session: Poster session 15
Resources:
Abstract
437TiP - An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)
Presenter: Mridula George
Session: Poster session 15
Resources:
Abstract
438TiP - Trastuzumab deruxtecan with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: An exploratory, multi-center, single-arm, phase II study (TROPHY, trial in progress)
Presenter: Ying Fan
Session: Poster session 15
Resources:
Abstract
439TiP - AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors
Presenter: Afshin Dowlati
Session: Poster session 15
Resources:
Abstract
517P - Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study
Presenter: Aziz Zaanan
Session: Poster session 15
Resources:
Abstract
519P - Cetuximab plus capecitabine versus cetuximab as maintenance treatment in Chinese patients with RAS/BRAF wild type metastatic colorectal cancer (mCRC): A phase III, multicenter, open-label, randomized study (C-CLASSIC study)
Presenter: Dongsheng Zhang
Session: Poster session 15
Resources:
Abstract
520P - Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 trial
Presenter: Rocio Garcia-Carbonero
Session: Poster session 15
Resources:
Abstract
521P - XELOX +bev +tislelizumab for first-line treatment of MSS/pMMR RAS-mutated mCRC: A single-arm, phase II study
Presenter: Kai Ou
Session: Poster session 15
Resources:
Abstract
522P - Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): Subgroup analyses of WJOG9216G (RECAST)
Presenter: Kazuhiro Shiraishi
Session: Poster session 15
Resources:
Abstract